Application of Box-Behnken design for optimization of formulation parameters for nanostructured lipid carriers of candesartan cilexetil

Asian Journal of Pharmaceutics

Volumn 8, Issue 2, 2014, Pages 81-89

  Thakkar, Hetal P ^a   Desai, Jagruti L ^a   Parmar, Mayur P ^a  

^a M S UNIVERSITY OF BARODA   (India)

Author keywords

Candesartan; hypertension; nanostructured lipid carriers; oral bioavailability partition study

Indexed keywords

BUFFER; CANDESARTAN HEXETIL; GLYCEROL STEARATE; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OCTANOIN; PHOSPHATE; UNCLASSIFIED DRUG;

ARTICLE; BOX BEHNKEN DESIGN; CHEMICAL PROCEDURES; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BIOAVAILABILITY; DRUG RELEASE; FREEZING; IN VITRO STUDY; MELTING POINT; MISCIBILITY; MOLECULAR STABILITY; NANOEMULSION; PARTICLE SIZE; PROCESS OPTIMIZATION; RESEARCH; ROOM TEMPERATURE; SIMULATION; STOMACH JUICE; STOMACH PH; THERMOGRAPHY; ZETA POTENTIAL;

EID: 84903207453     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.134921     Document Type: Article

References (41)

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet 2005;365:217-23. (Pubitemid 40138015)
2. High blood pressure and cholesterol: Out of control in US. Atlanta. Available from: Http://www.cdc.gov/Features/Vitalsigns/ CardiovascularDisease. [Last cited on 2013 Apr 25].
3. Tadevosyan A, Maclaughlin EJ, Karamyan VT. Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: Focus on patient outcomes. Patient Relat Outcome Meas 2011;2:27-39.
4. David PW. Antihypertensive drugs. In: Charles R, Craig RE, editors. Modern Pharmacology with Clinical Applications. Beltimore: Lippincott Williams and Wilkins; 1997. p. 225-38.
5. Ferreiros N, Dresen S, Alonso RM, Weinmann W. Hydrolysis and transesterification reactions of candesartan cilexetil observed during the solid phase extraction procedure. J Chromatogr B Analyt Technol Biomed Life Sci 2007;855:134-8. (Pubitemid 47212003)
6. Nishida Y, Takahashi Y, Nakayama T, Soma M, Asai S. Comparative effect of olmesartan and candesartan on lipid metabolism and renal function in patients with hypertension: A retrospective observational study. Cardiovasc Diabetol 2011;10:74.
7. Nekkanti V, Karatgi P, Prabhu R, Pillai R. Solid self-microemulsifying formulation for candesartan cilexetil. AAPS PharmSciTech 2010;11:9-17.
8. Al Omari AA, Al Omari MM, Badwan AA, Al-Sou'od KA. Effect of cyclodextrins on the solubility and stability of candesartan cilexetil in solution and solid state. J Pharm Biomed Anal 2011;54:503-9.
9. Sayyad FJ, Tulsankar SL, Kolap UB. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. J Pharm Res 2013;7:381-8.
10. Zhang Z, Gao F, Bu H, Xiao J, Li Y. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: In vitro characteristics and absorption mechanism in rats. Nanomedicine 2012;8:740-7.
11. Gao F, Zhang Z, Bu H, Huang Y, Gao Z, Shen J, et al. Nanoemulsion improves the oral absorption of candesartan cilexetil in rats: Performance and mechanism. J Control Release 2011;149:168-74.
12. Burcham DL, Maurin MB, Hausner EA, Huang SM. Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. Biopharm Drug Dispos 1997;18:737-42. (Pubitemid 27475189)
13. Shafiq S, Shakeel F, Talegaonkar S, Ahmad FJ, Khar RK, Ali M. Development and bioavailability assessment of ramipril nanoemulsion formulation. Eur J Pharm Biopharm 2007;66:227-43. (Pubitemid 46667230)
14. Venishetty VK, Chede R, Komuravelli R, Adepu L, Sistla R, Diwan PV. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B Biointerfaces 2012;95:1-9.
15. Severino P, Andreani T, Macedo AS, Fangueiro JF, Santana MH, Silva AM, et al. Current state-of-Art and new trends on lipid nanoparticles (SLN and NLC) for oral drug delivery. J Drug Deliv 2012;2012:750891.
16. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-A review of the state of the art. Eur J Pharm Biopharm 2000;50:161-77. (Pubitemid 30326695)
17. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405.
18. Kasongo KW, Shegokar R, Müller RH, Walker RB. Formulation development and in vitro evaluation of didanosine-loaded nanostructured lipid carriers for the potential treatment of AIDS dementia complex. Drug Dev Ind Pharm 2011;37:396-407.
19. Gohel MC, Amin AF. Formulation optimization of controlled release diclofenac sodium microspheres using factorial design. J Control Release 1998;51:115-22. (Pubitemid 28252862)
20. Nazzal S, Khan MA. Response surface methodology for the optimization of ubiquinone self-nanoemulsified drug delivery system. AAPS Pharm Sci Tech 2002;3:E3.
21. Gareth A. Lewis DM, Phan-Tan-Luu R. Pharmaceutical Experimental Design. New York, Basel: Marcel Deckker Inc.; 2005.
22. Joshi M, Patravale V. Formulation and evaluation of nanostructured lipid carrier (NLC)-based gel of valdecoxib. Drug Dev Ind Pharm 2006;32:911-8. (Pubitemid 44359752)
23. Doktorovová S, Araújo J, Garcia ML, Rakovský E, Souto EB. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B Biointerfaces 2010;75:538-42.
24. Aji Alex MR, Chacko AJ, Jose S, Souto EB. Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Eur J Pharm Sci 2011;42:11-8.
25. Box GE, Behnken DW. Some new three-level designs for the study of quantitative variables. Technometrics 1960;2:455-75.
26. Dong CH, Xie XQ, Wang XL, Zhan Y, Yao YJ. Application of Box-Behnken design in optimisation for polysaccharides extraction from cultured mycelium of Cordyceps sinensis. Food Bioprod Process 2009;87:139-44.
27. Gulbake A, Jain A, Khare P, Jain SK. Solid lipid nanoparticles bearing oxybenzone: In-vitro and in-vivo evaluation. J Microencapsul 2010;27:226-33.
28. Unruh T, Bunjes H, Westsen K. Observation of size-dependent melting in lipid nanoparticles. J Phys Chem 1999;103:10373-7. (Pubitemid 129614093)
29. ICH Q 1 A (R2). Stability Testing of New Drug Substances and Products (CPMP/ICH/2736/99); 2003.
30. Gonzalez-Mira E, Egea MA, Garcia ML, Souto EB. Design and ocular tolerance of flurbiprofen loaded ultrasound-engineered NLC. Colloids Surf B Biointerfaces 2010;81:412-21.
31. Uner M, Yener G. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine 2007;2:289-300. (Pubitemid 350047774)
32. Woitiski CB, Veiga F, Ribeiro A, Neufeld R. Design for optimization of nanoparticles integrating biomaterials for orally dosed insulin. Eur J Pharm Biopharm 2009;73:25-33.
33. Gannu R, Yamsani VV, Yamsani SK, Palem CR, Yamsani MR. Optimization of hydrogels for transdermal delivery of lisinopril by Box-Behnken statistical design. AAPS Pharm Sci Tech 2009;10:505-14.
34. Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, et al. Preparation and characterization of silybin-loaded nanostructured lipid carriers. Drug Deliv 2010;17:11-8.
35. Finney J. The structural basis of the hydrohobic interaction. In: Bellissent-Funel MC, editor. Hydration Processes in Biology: Theoretical and Experimental Approaches. France: IOS Press; 1998. p. 115-26.
36. Han F, Sanming L, Yin R, Liu H, Xu L. Effect of surfactants on the formation and characterization of a new type of colloidal drug delivery system: Nanostructured lipid carriers. Colloids Surf A Physicochem Eng Asp 2008;315:210-6. (Pubitemid 350298857)
37. Unruh T, Bunjes H, Westesen K, Koch MH, Investigations on the melting behaviour of triglyceride nanoparticles. Colloid Polym Sci 2001;279:398-403. (Pubitemid 32294168)
38. Nekkanti V, Pillai R, Venkateshwarlu V, Harisudhan T. Development and characterization of solid oral dosage form incorporating candesartan nanoparticles. Pharm Dev Technol 2009;14:290-8.
39. Chakraborty S, Shukla D, Mishra B, Singh S. Lipid-An emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 2009;73:1-15.
40. Beloqui A, Solinís MA, Delgado A, Evora C, Isla A, Rodríguez-Gascón A. Fate of nanostructured lipid carriers (NLCs) following the oral route: Design, pharmacokinetics and biodistribution. J Microencapsul 2014;31:1-8.
41. Joshi M, Patravale V. Nanostructured lipid carrier (NLC) based gel of celecoxib. Int J Pharm 2008;346:124-32. (Pubitemid 350110507)